Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2019-2025

Report / Search Code: RnM3430179  Publish Date: 20 May, 2019

Price
1-user PDF : $ 3900.0  Site PDF : $ 5850.0  Enterprise PDF : $ 7800.0

Description:
Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain. The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market.

In 2018, the global Recurrent Glioblastoma Multiforme (GBM) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Recurrent Glioblastoma Multiforme (GBM) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recurrent Glioblastoma Multiforme (GBM) Treatment development in United States, Europe and China.

The key players covered in this study
- Astrazeneca
- Roche
- GlaxoSmithKline
- Merck
- Pfizer
- AngioChem
- Vascular Biogeneics

Market segment by Type, the product can be split into
- Oral Medications
- Temozolomide
- Radiosensitizers
- Nitrosoureas Drugs
- Radiation Therapy
- Chemotherapy

Market segment by Application, split into
- Hospitals
- Clinics
- Ambulatory Surgical Centers

Market segment by Regions/Countries, this report covers
- United States
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America

The study objectives of this report are:
- To analyze global Recurrent Glioblastoma Multiforme (GBM) Treatment status, future forecast, growth opportunity, key market and key players.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme (GBM) Treatment are as follows:
- History Year: 2014-2018
- Base Year: 2018
- Estimated Year: 2019
- Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents:

Table of Contents

1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
  - 1.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (2014-2025)
  - 1.4.2 Oral Medications
  - 1.4.3 Temozolomide
  - 1.4.4 Radiosensitizers
1.4.5 Nitrosoureas Drugs
1.4.6 Radiation Therapy
1.4.7 Chemotherapy

1.5 Market by Application
1.5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers

1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size
2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Manufacturers
3.1.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Manufacturers (2014-2019)
3.1.3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
3.3 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product/Solution/Service
3.4 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2014-2019)

5 United States
5.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in United States
5.3 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
5.4 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

6 Europe
6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Europe
6.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
6.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

7 China
7.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in China
7.3 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
7.4 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

8 Japan
8.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Japan
8.3 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
8.4 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

9 Southeast Asia
9.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Southeast Asia
9.3 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
9.4 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

10 India
10.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in India
10.3 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
10.4 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

11 Central & South America
11.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Central & South America
11.3 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
11.4 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

12 International Players Profiles
12.1 Astrazeneca
12.1.1 Astrazeneca Company Details
12.1.2 Company Description and Business Overview
12.1.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.1.5 Astrazeneca Recent Development
12.2 Roche
12.2.1 Roche Company Details
12.2.2 Company Description and Business Overview
12.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
12.2.5 Roche Recent Development

12.3 GlaxoSmithKline
12.3.1 GlaxoSmithKline Company Details
12.3.2 Company Description and Business Overview
12.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
12.3.5 GlaxoSmithKline Recent Development

12.4 Merck
12.4.1 Merck Company Details
12.4.2 Company Description and Business Overview
12.4.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.4.5 Merck Recent Development

12.5 Pfizer
12.5.1 Pfizer Company Details
12.5.2 Company Description and Business Overview
12.5.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
12.5.5 Pfizer Recent Development

12.6 AngioChem
12.6.1 AngioChem Company Details
12.6.2 Company Description and Business Overview
12.6.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.6.5 AngioChem Recent Development

12.7 Vascular Biogeneics
12.7.1 Vascular Biogeneics Company Details
12.7.2 Company Description and Business Overview
12.7.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
12.7.5 Vascular Biogeneics Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources

15.2 Disclaimer